SBIR/STTR Research Award

Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging

Award identifier 4adac7ae3bfdaac47ad8b6c6e0a50a6cf67a2056fb25560b91622a8dd96d32ffAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,809,974

Program and phase

SBIR · Phase II

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Molecular Instruments, Inc.
Proposal award date
2024-09-01
Contract end date
2026-08-31
UEI
SP8PV4N4ZED9
Solicitation number
PA22-176
Topic code
400

Research abstract

Project Summary Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging Encoded in the genome of each organism, biological circuits direct development, maintain integrity in the face of attacks, control responses to environmental stimuli, and sometimes malfunction to cause disease. RNA in situ hybridization (RNA-ISH) and immunohistochemistry (IHC) methods provide drug developers, pathologists, and biologists with critical windows into the spatial organization of this circuitry, enabling imaging of RNA and protein expression in an anatomical context. While it is desirable to perform multiplex experiments in which a panel of targets is imaged with single-molecule sensitivity at low magnification over a large field-of-view within intact tissue, the dominant automated RNA-ISH and IHC methods struggle to provide these capabilities. First, multiplexing is cumbersome, requiring serial enzyme-mediated signal amplification for each target in succession (currently limited to 2-plex for chromogenic staining of RNA targets and often requiring probe stripping for protein targets). Second, sensitivity is routinely limiting at the low magnifications essential to rapid screening of large fields-of-view; this problem is only exacerbated for short RNA targets, low-expression targets, and archival tissue sections. Third, there is no unified technology for automated imaging of RNA and protein targets. Current automated RNA-ISH approaches require a protease pretreatment step that digests proteins to enable large reagents to penetrate the sample; this digestion step comes at a high cost both because it damages the tissue morphology and because it makes it challenging or impossible to image protein targets in the same sample. Collectively, these multi-decade technology gaps are significant impediments to drug development, clinical pathology, and biological research, undermining multi-dimensional analyses of genetic regulatory networks in an anatomical context. To overcome these challenges, in situ amplification based on the mechanism of hybridization chain reaction (HCR) draws on concepts from the emerging discipline of dynamic nucleic acid nanotechnology to provide the first unified framework for simultaneous RNA and protein imaging, achieving multiple breakthroughs to enable multiplex, quantitative, high-resolution RNA and protein imaging in highly autofluorescent samples. To empower high-velocity biopharma drug development and clinical diagnostics workflows, the proposed R&D will build on the unique capabilities of HCR to: 1) engineer a novel chromogenic signal amplification cascade to enable automated ultrasensitive 4-plex RNA chromogenic in situ hybridization (RNA-CISH), IHC, and simultaneous RNA-CISH/IHC at low magnification for rapid whole-slide scanning, 2) engineer a novel enzyme-free fluorescent signal ampli- fication cascade to enable automated ultrasensitive 4-plex RNA fluorescence in situ hybridization (RNA-FISH), immunofluorescence (IF), and simultaneous RNA-FISH/IF at low magnification for rapid whole-slide scanning. These capabilities will enable drug developers, pathologists, and biologists to perform automated, ultrasensi- tive, multiplex analyses of RNAs and proteins in an anatomical context using either chromogenic or fluorescent workflows.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $3,266,762. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.